[go: up one dir, main page]

US3225031A - Phenyl-benzazepines and methods for their manufacture - Google Patents

Phenyl-benzazepines and methods for their manufacture Download PDF

Info

Publication number
US3225031A
US3225031A US296431A US29643163A US3225031A US 3225031 A US3225031 A US 3225031A US 296431 A US296431 A US 296431A US 29643163 A US29643163 A US 29643163A US 3225031 A US3225031 A US 3225031A
Authority
US
United States
Prior art keywords
group
phenyl
ether
benzazepine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US296431A
Inventor
Margaret H Sherlock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to US296431A priority Critical patent/US3225031A/en
Application granted granted Critical
Publication of US3225031A publication Critical patent/US3225031A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines

Definitions

  • the invention sought to be patented in its composition aspect is described as residing in the concept of a chemical compound having the molecular structure of 2,3,4,5-tetrahydro-lH-Z-benzazepine having a phenyl substituent at the position and at the 2-position having a member of the group consisting of hydrogen, lower alkyl and phenyl lower alkyl. Included within this concept are the acid addition salts and the quaternary salts thereof.
  • the invention sought to be patented in its process aspect is described as residing in the concept of that step which comprises heating at an elevated temperature a member of the group consisting of an o-R R -aminomethyldiphenylmethane and the acid addition salts thereof having a lower alkyl group of at least two carbon atoms attached to the methane carbon atom, the fi-carbon atom of said alkyl group having a substituent of the group represented by R R amino-, halogen (preferably chloro or bromo), tosyloxy and mesyloXy, wherein R and R represent methyl and benzyl, said heating at elevated temperature continued until substantial transformation into a tetrahydrobenzazepine compound is effected. Following the heating step, it may be necessary to de-alkylhalogenate depending upon the nature of the product formed.
  • the tangible embodiments are of value as anticholinergic or parasympathetic blocking agents.
  • the tangible embodiments of this invention are chemical compounds having the structural formula wherein R is a member of the group consisting of H, lower alkyl and phenyl-lower alkyl, and X is a member of the group consisting of H and methyl. Included within the foregoing are the acid addition salts and quaternary salts of the bases depicted therein. The system of numbering the nuclear atoms is set forth in the formula.
  • the tangible embodiments of this invention are prepared by heating an o-dimethylarninomethyldiphenylmethane or an o-dibenzylaminomethyldiphenylmethane or an o-N-benzyl-N-methylaminomethyldiphenylmethane, the methane carbon atom of which bears a lower alkyl group having at least two carbon atoms, the B-carbon atom of said alkyl group bearing a substituent such as dimethylamino, dibenzylamino, halogen (preferably chloro or bromo), tosyloXy and mesyloxy.
  • the cyclized product is a tertiary amine of Formula I.
  • the substituent is halogen
  • the product formed is a quaternary salt which may be de-alkylhalogenated to form the tertiary amine.
  • precursors of the aforementioned starting materials such as those possessing a hydroxy or lower alkoxy' (preferably methoxy or ethoxy) group in the B-position of the aforementioned alkyl group, may be used by reacting said oxy compounds with a reagent which replaces the oxy function by halogen and then heating the halogenated prodnot.
  • a reagent which replaces the oxy function by halogen and then heating the halogenated prodnot.
  • the substituent is ethoxy
  • such a compound is heated with a hydrohalic acid, preferably hydrobromic acid, whereby the ethoxy group is replaced by brorno.
  • the o-R R -aminomethyl group simultaneously may form a hydrobromide salt.
  • This intermediate which is the starting material of the process aspect of my invention is preferably not isolated but is heated in situ in the presence of hydrobromic acid resulting in in situ ring closure forming a benzazepinium quaternary bromide.
  • This method is outlined in further detail in subsequent passages.
  • the substituent is hydroxy
  • such a compound is reacted with thionyl chloride, for example, and heated in situ.
  • the reaction with thionyl chloride effects replacement of the hydroxy by chloro with probable simultaneous formation of a hydrochloride of the o-R R -aminomethyl group.
  • ring closure occurs with the formation of a benzazepinium quaternary chloride.
  • This reaction also is set forth in more detail in subsequent passages. It is thus apparent that such reactions whereby the starting materials of my invention in its process aspect are formed in situ and acted upon in situ are full equivalents of my invention in its process aspect.
  • a preferred method for preparing the tangible embodiment represented by Formula I, wherein R is: methyl consists of alkylating o-dimethylaminomethyldiphenylmethane (II) with fl-bromoethyl ethyl ether in the presence of a basic condensing agent such as sodamide in liquid ammonia.
  • the fl-cthoxyethyl analog (III) formed thereby is heated with a strong acid, preferably concentrated hydrobromic acid, whereby the benzazepinium bromide (IV) is formed.
  • the bromo hydrobromide formed by the action of hydrobromic acid is the starting material of my invention in its process aspect and is acted upon in situ by heating.
  • Heating the quaternary salt eliminates the element of methyl bromide resulting in the formation of tertiary amine (V).
  • the quaternary salt may alternatively be de-methobrominated by reaction With lithium aluminum hydride or an alkali metal borohydride. This reaction sequence is depicted as follows:
  • dimethylaminoethyl chloride may carry an alkyl substituent such as methyl or ethyl on either one of itscarbon atoms, for example, 2-dimethylaminopropyl chloride.
  • alkyl substituent such as methyl or ethyl on either one of itscarbon atoms, for example, 2-dimethylaminopropyl chloride.
  • Two products are accordingly formed with this reagent: one having the alkyl substituent in the 2-position and the other in the 3-position.
  • the quaternary ammonium salts are prepared in the known manner by reacting the tertiary amine of Formula I with a quaternizing agent such as a lower alkyl halide or sulfate.
  • a quaternizing agent such as a lower alkyl halide or sulfate.
  • An alternative method is that wherein an o-dimethylaminomethyldiphenyl methane (II) is alkylated with an ethylene oxide as described heretofore and the hydroxy compound (XIII) treated with thionyl chloride.
  • R represents H or methyl. It is necessary to treat the product of the reaction of XIII with thionyl chloride with alkali in order to prepare the free base XIV.
  • the starting materials shown are either o-dimethylaminomethyldiphenyl methanes or o-dibenzylaminomethyldiphenyl methanes.
  • a mixed alkylamino compound such as o-N-methyl-N-benzylaminomethyldiphenyl methane may also be utilized.
  • the benzyl group is the more labile and is eliminated upon ring closure or by catalytic hydrogenation.
  • aminomethyldiphenylmethanes may carry one or more common substituents in either one or both of the phenyl rings.
  • Such common substituents are halogen (preferably chloro), lower alkoxy (preferably methoxy), lower alkyl (preferably methyl), hydroxy, lower alkanoyloxy, and obvious equivalent thereof. These substituents do not materially alter the biological properties of the unsubstituted compound making for diiferences in degree rather than kind. I therefore consider such ring substituted compounds as the full equivalent of the corresponding unsubstituted compounds of Formula I and within the concept of the composition aspect as set forth therein.
  • the precursors for the starting materials of the process aspect of my invention i.e., the o-disubstituted aminomethyldiphenylmethanes are prepared from the reaction of an appropriately substituted o-benzylbenzoic acid (XVI) and dimethylamine (or dibenzylamine or methylbenzylarnine). Heating these two reagents together at temperatures above 100 C. permits the reaction to proceed with concomitant removal of water and results in the formation of an intermediate amide (XVII) which is reduced with lithium aluminum hydride, for example,
  • compositions contemplated herein are bases, acid addition salts and quaternary ammonium salts thereof.
  • the acid addition salts are preferably the non-toxic pharmaceutically acceptable salts of the bases with mineral acids such as hydrochloric acid.
  • salts with organic acids such as maleic and the like. These salts are prepared by standard methods such as mixing equivalent quantities of the base and the acid in a solvent in which the salt is insoluble. The salt is removed therefrom by filtration and is purified by recrystallization from a polar solvent like ethyl acetate or alcohol-ether.
  • These acid addition salts have inherently the same biological properties as the free bases but provide a more convenient form for physically handling and formulating the bases.
  • the quaternary salts contemplated are benzyl and lower alkyl and phenyl lower alkyl quaternary salts with the anion being non-toxic and pharmaceutically acceptable. Representative of such anions are halide (chloride, bromide), sulfate and the like.
  • the quaternary salts are prepared either as described heretofore or in the standard fashion by mixing a solution of the tertiary amine and a lower alkyl halide or sulfate in a solvent in which the quaternary salt is insoluble such as ether. The quaternary salt is removed by filtration and purified in a standard manner.
  • PREPARATION l 0-Benzyl-N,N-dimethy lbenzamz'de Melt o-benzylbenzoic acid. Bubble dimethylamine through the melt for 2-3 hours. Cool, triturate the solids with ether and filter. Wash the ether with dilute hydrochloric acid, then with Water and then with 10% sodium carbonate solution. Dry the ether over sodium sulfate and evaporate to a residue consisting of the amide of this example.
  • Nuclear substituted analogs of the compound of this example are prepared from the correspondingly substituted benzylbenzoic acids such as, for example, o-(pchlorobenzyl)-benzoic acid which as per Preparations 1 and 3 give rise to o-dimethylaminornethyl-p-chlorodiphenylmethane.
  • EXADIPLE 2 5 -p/zenyl-2,2,3-trimeZhyl-2,3,4,5 -retrahydr0-1 H -2- benzazepinium chloride Suspend sodamide (from 3.72 g. of sodium) in 200 ml. of liquid ammonia and add 31.7 g. of o-dimethylaminomethyldiphenyl methane (Preparation 3). Stir the red solution for 30 minutes and then add 17.1 g. of propylene oxide. Stir and allow the ammonia to evaporate. Add ice water and extract the mixture with ether. Dry the ether solution and distil collecting that fraction boiling at 166167 C.
  • EXAMPLE 3 a- (ti-Ethoxyet/zyl) -0-dibenzylaminomethyldiphenyl methane
  • the compound of this example is prepared via the first step in the alternate procedure of Example 1 utilizing postassium amide (from 2 g. of potassium), 250 ml. of liquid ammonia, 18.8 g. of o-dibenzylaminornethyldiphenyl methane and 7.7 g. of B-bromoethyl ether.
  • EXAMPLE 4 5-phenyl-2,2diberzzy[-2,3,4,5-tetrahydr0-1H-2- benzazepinium bromide Dissolve 12.5 g. of the compound of Example 3 in 100 ml. of 48% hydrobromic acid and reflux for 20-24 hours. Concentrate to a residue in vacuo and crystallize from ethanol-ether to obtain the quaternary salt of this example.
  • EXAMPLE 8 -phenyl-2,3-dimethyl-2,3,4,5-tetrahydr0-1H-2- benzazepine Pyrolize the quaternary salt of Example 2 at 300320 C. collecting that distillate boiling at 190-206 C./4.7 mm. Upon cooling, the distillate forms a glassy solid consisting of the compounds of this example. A maleate salt prepared from the base and maleic acid in a known manner melts at 119-121 C.
  • X is a member of the group consisting of H and methyl and R is a member of the group consisting of H, lower alkyl and phenyl lower alkyl.
  • the step which comprises heating at an elevated temperature a member of the group consisting of an o-R R -aminoethyldiphenylmethane and the acid addition salts thereof, having a lower alkyl group of at least two carbon atoms attached to the methane carbon atoms, the B-carbon atom of said alkyl group bearing a substituent selected from the group consisting of R R -amino and halogeno, wherein R and R are members of the group consisting of methyl and benzyl until substantial transformation into a tetrahydrobenzazepine compound is effected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent 3,225,031 PHENYL-BENZAZEPINES AND METHODS FOR THEIR MANUFACTURE Margaret H. Sherlock, Bloomfield, N.J., assignor to Schering Corporation, Bloomfield, N.l., a corporation of New Jersey No Drawing. Filed July 22, 1963, Ser. No. 296,431 11 Claims. (Cl. 260-239) This invention relates to compositions of matter identifiable in the art of chemistry as S-phenyl-tetrahydro-Z- benzazepines and to processes for making and using such compositions.
The invention sought to be patented in its composition aspect is described as residing in the concept of a chemical compound having the molecular structure of 2,3,4,5-tetrahydro-lH-Z-benzazepine having a phenyl substituent at the position and at the 2-position having a member of the group consisting of hydrogen, lower alkyl and phenyl lower alkyl. Included within this concept are the acid addition salts and the quaternary salts thereof.
The invention sought to be patented in its process aspect is described as residing in the concept of that step which comprises heating at an elevated temperature a member of the group consisting of an o-R R -aminomethyldiphenylmethane and the acid addition salts thereof having a lower alkyl group of at least two carbon atoms attached to the methane carbon atom, the fi-carbon atom of said alkyl group having a substituent of the group represented by R R amino-, halogen (preferably chloro or bromo), tosyloxy and mesyloXy, wherein R and R represent methyl and benzyl, said heating at elevated temperature continued until substantial transformation into a tetrahydrobenzazepine compound is effected. Following the heating step, it may be necessary to de-alkylhalogenate depending upon the nature of the product formed.
The tangible embodiments of the invention in the form of the free base or acid addition salt thereof, possess the inherent applied use characteristics of exerting an effect upon the central nervous system manifest by a stimulant action as determined by pharmacological evaluation. They are thus useful in elevating mood, or establishing a wakefulness. At higher doses than that required to produce a stimulant effect, these compounds elicit an analgesic response. In the form of their nontoxic quaternary salts, the tangible embodiments are of value as anticholinergic or parasympathetic blocking agents.
The tangible embodiments of this invention are chemical compounds having the structural formula wherein R is a member of the group consisting of H, lower alkyl and phenyl-lower alkyl, and X is a member of the group consisting of H and methyl. Included within the foregoing are the acid addition salts and quaternary salts of the bases depicted therein. The system of numbering the nuclear atoms is set forth in the formula.
As stated heretofore, the tangible embodiments of this invention are prepared by heating an o-dimethylarninomethyldiphenylmethane or an o-dibenzylaminomethyldiphenylmethane or an o-N-benzyl-N-methylaminomethyldiphenylmethane, the methane carbon atom of which bears a lower alkyl group having at least two carbon atoms, the B-carbon atom of said alkyl group bearing a substituent such as dimethylamino, dibenzylamino, halogen (preferably chloro or bromo), tosyloXy and mesyloxy. Upon heating such a material at substantially elevated temperatures, ring closure occurs resulting in a compound of Formula I. Where the aforementioned substituent is an amino function as described heretofore, the cyclized product is a tertiary amine of Formula I. Where the substituent is halogen, the product formed is a quaternary salt which may be de-alkylhalogenated to form the tertiary amine.
It will be apparent to one skilled in the art that precursors of the aforementioned starting materials, such as those possessing a hydroxy or lower alkoxy' (preferably methoxy or ethoxy) group in the B-position of the aforementioned alkyl group, may be used by reacting said oxy compounds with a reagent which replaces the oxy function by halogen and then heating the halogenated prodnot. For example, where the substituent is ethoxy, such a compound is heated with a hydrohalic acid, preferably hydrobromic acid, whereby the ethoxy group is replaced by brorno. Indeed, the o-R R -aminomethyl group simultaneously may form a hydrobromide salt. This intermediate, which is the starting material of the process aspect of my invention is preferably not isolated but is heated in situ in the presence of hydrobromic acid resulting in in situ ring closure forming a benzazepinium quaternary bromide. This method is outlined in further detail in subsequent passages. On the other hand, where the substituent is hydroxy, such a compound is reacted with thionyl chloride, for example, and heated in situ. The reaction with thionyl chloride effects replacement of the hydroxy by chloro with probable simultaneous formation of a hydrochloride of the o-R R -aminomethyl group. Upon heating in situ, ring closure occurs with the formation of a benzazepinium quaternary chloride. This reaction also is set forth in more detail in subsequent passages. It is thus apparent that such reactions whereby the starting materials of my invention in its process aspect are formed in situ and acted upon in situ are full equivalents of my invention in its process aspect.
A preferred method for preparing the tangible embodiment represented by Formula I, wherein R is: methyl consists of alkylating o-dimethylaminomethyldiphenylmethane (II) with fl-bromoethyl ethyl ether in the presence of a basic condensing agent such as sodamide in liquid ammonia. The fl-cthoxyethyl analog (III) formed thereby is heated with a strong acid, preferably concentrated hydrobromic acid, whereby the benzazepinium bromide (IV) is formed. (As stated heretofore, the bromo hydrobromide formed by the action of hydrobromic acid is the starting material of my invention in its process aspect and is acted upon in situ by heating.) Heating the quaternary salt eliminates the element of methyl bromide resulting in the formation of tertiary amine (V). The quaternary salt may alternatively be de-methobrominated by reaction With lithium aluminum hydride or an alkali metal borohydride. This reaction sequence is depicted as follows:
In place of the bromoethyl ether, there may be employed an alkylating agent such as dimethylaminoethyl chloride. The diamine, VI, thus formed is then transformed into its monohydrochloride salt and heated whereby cyclization occurs. The free base (VII) is obtained by rendering the cyclized residue alkaline and extracting with an organic solvent such as ether. This reaction sequence is shown as follows:
ClCHzCH N(CHa)2 It is apparent that the dimethylaminoethyl chloride may carry an alkyl substituent such as methyl or ethyl on either one of itscarbon atoms, for example, 2-dimethylaminopropyl chloride. Two products are accordingly formed with this reagent: one having the alkyl substituent in the 2-position and the other in the 3-position.
A further method for arriving at the compounds of Formula I wherein R is hydrogen is that depicted by the following reaction scheme:
C HQN (bcnzyl) 2 VIII $0012 7 A III H v A in vacuo I 311; (I: C Hz I I HzN (benzyl) 2 0 H7 C H: I
I I-I;4N+ C1 0 H IX X H Pd/C H 0 Hz I C Hi (I:
OH: i I H: Hz-N-CHC5H5 I'Iz-III II XI XII In this sequence, o-dibenzylaminodiphenylmethane (VIII) is alkylated with ethylene oxide to produce the hydroxy intermediate (IX). Replacement of the hydroxy group by chlorine is effected by thionyl chloride and heating results in the formation of the quaternary benzyl chloride (X). (An intermediary chlorohydrochloride which is the starting material for the process aspect of my invention is formed and acted upon in situ.) Elimination of benzyl chloride yielding XI is accomplished by heating the dry quaternary salt in vacuo and debenzylation effected by reduction with hydrogen on a palladium charcoal catalyst. There is thus obtained the secondary amine XII. The nitrogen atom of XII may now be alkylated, if desired, by known means to yield the tertiary amine, i.e. R=lower alkyl or phenyl lower alkyl.
It will be apparent to one skilled in the art that by utilizing 1,2-pr0pylene oxide in place of ethylene oxide analogous reactions take place with the methyl group appearing as a substituent on the hete-rocyclic ring, most probably in the 3-position. This accordingly is a means for preparing such an analogous product.
The quaternary ammonium salts are prepared in the known manner by reacting the tertiary amine of Formula I with a quaternizing agent such as a lower alkyl halide or sulfate. An alternative method is that wherein an o-dimethylaminomethyldiphenyl methane (II) is alkylated with an ethylene oxide as described heretofore and the hydroxy compound (XIII) treated with thionyl chloride.
The chloro compound (XIV) formed thereby upon heating is cyclized to yield the methyl quarternary salt (XV).
In the foregoing R represents H or methyl. It is necessary to treat the product of the reaction of XIII with thionyl chloride with alkali in order to prepare the free base XIV.
In the reaction schemes illustrated heretofore, the starting materials shown are either o-dimethylaminomethyldiphenyl methanes or o-dibenzylaminomethyldiphenyl methanes. A mixed alkylamino compound such as o-N-methyl-N-benzylaminomethyldiphenyl methane may also be utilized. Under these circumstances, the benzyl group is the more labile and is eliminated upon ring closure or by catalytic hydrogenation.
It will be apparent to one skilled in the art that the aminomethyldiphenylmethanes may carry one or more common substituents in either one or both of the phenyl rings. Such common substituents are halogen (preferably chloro), lower alkoxy (preferably methoxy), lower alkyl (preferably methyl), hydroxy, lower alkanoyloxy, and obvious equivalent thereof. These substituents do not materially alter the biological properties of the unsubstituted compound making for diiferences in degree rather than kind. I therefore consider such ring substituted compounds as the full equivalent of the corresponding unsubstituted compounds of Formula I and within the concept of the composition aspect as set forth therein.
It will also be apparent to one skilled in the art that the carbon atom at the 5-position is asymmetric and thus the compounds depicted by the formulae and description contained herein are in actuality racemates. Resolution of the racemates into its optically active isomers may accordingly be effected by the standard techniques such as employment of an optically active acid, for example, in the case of the free bases. The optically active isomers are considered fully within the scope and purview of this invention.
The precursors for the starting materials of the process aspect of my invention, i.e., the o-disubstituted aminomethyldiphenylmethanes are prepared from the reaction of an appropriately substituted o-benzylbenzoic acid (XVI) and dimethylamine (or dibenzylamine or methylbenzylarnine). Heating these two reagents together at temperatures above 100 C. permits the reaction to proceed with concomitant removal of water and results in the formation of an intermediate amide (XVII) which is reduced with lithium aluminum hydride, for example,
to yield the requisite o-disubstituted aminomethyldiphenylmethane (XVIII). This sequence of reactions is illus trated as follows:
O O OH C ONRJR:
XVI XVII l LiAlH4 OHrN i n XVIII In this reaction R and R represent methyl or benzyl. It is apparent that conversion of the benzylbenzoic acid (XVI) to its acid chloride followed by treatment with the secondary amine represents an alternate and obviously equivalent method for preparing XVII. The benzylbenzoic acids (XVI) are prepared by methods fully described in the art which includes those benzylbenzoic acids having nuclear substituents as set forth above. Thus in order to prepare a tangible embodiment of this invention as represented by Formula I but including a substituent on one or both of the aromatic rings, the correspondingly substituted benzylbenzoic acid is utilized.
As set forth in the statement of concept of the tangible embodiment of the invention, the compositions contemplated herein are bases, acid addition salts and quaternary ammonium salts thereof. The acid addition salts are preferably the non-toxic pharmaceutically acceptable salts of the bases with mineral acids such as hydrochloric acid. Also contemplated are salts with organic acids such as maleic and the like. These salts are prepared by standard methods such as mixing equivalent quantities of the base and the acid in a solvent in which the salt is insoluble. The salt is removed therefrom by filtration and is purified by recrystallization from a polar solvent like ethyl acetate or alcohol-ether. These acid addition salts have inherently the same biological properties as the free bases but provide a more convenient form for physically handling and formulating the bases.
The quaternary salts contemplated are benzyl and lower alkyl and phenyl lower alkyl quaternary salts with the anion being non-toxic and pharmaceutically acceptable. Representative of such anions are halide (chloride, bromide), sulfate and the like. The quaternary salts are prepared either as described heretofore or in the standard fashion by mixing a solution of the tertiary amine and a lower alkyl halide or sulfate in a solvent in which the quaternary salt is insoluble such as ether. The quaternary salt is removed by filtration and purified in a standard manner.
The following examples are illustrative of the preparation of the tangible embodiments of this invention. This invention is not limited to such examples but only by the appended claims and the obvious equivalents thereof taught herein.
PREPARATION l 0-Benzyl-N,N-dimethy lbenzamz'de Melt o-benzylbenzoic acid. Bubble dimethylamine through the melt for 2-3 hours. Cool, triturate the solids with ether and filter. Wash the ether with dilute hydrochloric acid, then with Water and then with 10% sodium carbonate solution. Dry the ether over sodium sulfate and evaporate to a residue consisting of the amide of this example.
7 PREPARATION 2 o-Benzyl-N,N-dibenzylbenzamide To a solution of o-benzylbenzoyl chloride in anhydrous benzene, add dropwise a solution of dibenzylamine in anhydrous benzene (slight excess of dibenzylamine). Stir for 1 hour. Extract the reaction mixture with 10% sodium carbonate solution then with water and then with dilute hydrochloric acid. Dry and evaporate to a residue consisting of the amide of this example.
PREPARATION 3 o-Dimethylaminomethyldfphenylmethzme Suspend 16 g. of lithium aluminum hydride in 500 ml. of anhydrous ether and add dropwise, a solution of 38 g. of o-benzyl-N,N-dimethylbenzamide (from Preparation 1) in 100 ml. of ether. Reflux for 6 hours, cool and pour into a cold 15% sodium hydroxide solution. Separate the ether layer and wash the aluminum salts with ether. Dry the ether solution and evaporate to a residue. Distill in vacuo obtaining the compound of this example, 36 g., B.P. 109112 C. (0.5 mm.).
In similar fashion, by utilizing the compound of Preparation 2 in the above procedure, there is obtained o-dibenzylaminomethyldiphenylmethane.
Nuclear substituted analogs of the compound of this example are prepared from the correspondingly substituted benzylbenzoic acids such as, for example, o-(pchlorobenzyl)-benzoic acid which as per Preparations 1 and 3 give rise to o-dimethylaminornethyl-p-chlorodiphenylmethane.
EXAMPLE 1 Z-methyl-5-plzenyl-2,3,4,5-tetrahydro-lH-Z-benzazepine IiI O in, (I311, C Hz-N While stirring a solution of potassium amide (prepared from 4.0 g. of potassium in 400 ml. of liquid ammonia) add 22.5 g. of o-dimethylaminomethyldiphenyl methane (from Preparation 3). Stir for 30 minutes and then add 13.5 g. of ,B-dimethylarninoethyl chloride. Allow the ammonia to evaporate. Add water and extract the mixture with ether. Dry the ether solution, concentrate and distil the residue in vacuo obtaining a-(fi-dimethylarninoethyl) o dimethylaminomethyldiphenyl methane, B.P. 142147 C./0.51.0 mm.
Dissolve 3.3 g. of the product obtained above in 5.4 ml. of water containing 1.95 g. of concentrated hydrochloric acid. Evaporate the solution to dryness and heat the mono-hydrochloride at 270290 C. until the evolution of gas (trimethylamine) ceases. Dissolve the residue in dilute hydrochloric acid, make alkaline with aqueous sodium carbonate solution and extract with ether. Dry the ether solution and concentrate to a residue. Crystallize from petroleum ether obtaining the compound of this example, M.P. 74-75 C.
An alternate procedure for preparing the benzazepine of this example is as follows:
Suspend sodamide (from 2.5 g. of sodium) in 400 ml. of liquid ammonia and add 22.5 g. of o-dimethylaminomethyldiphenyl methane. Stir for 30 minutes and then add 18.5 g. of fl-bromoethyl ether. Allow the ammonia to evaporate and then add 500 ml. of water. Extract with ether, dry the extracts, concentrate and distil in vacuo obtaining a (/5ethoxyethyl)-o-dimethylaminomethyldiphenyl methane, B.P. 145149 C./1 mm.
Dissolve 21.9 g. of the product obtained upon distillation in 125 ml. of 48% hydrobromic acid and reflux for 22-24 hours. Concentrate in vacuo to a residue and crystallize from ethanolether obtaining 5-phenyl-2,2-dimethyl-2,3 ,4, S-tetrahydro- 1H-2-benzazepinium bromide, M.P. 250253 C.
Pyrolyze the quaternary salt by heating at 300350 C. under vacuum (1-5 mm.) until no more distillate is formed. The distillate (B.P. 185-230 C./1-5 mm.) is crystallized from petroleum ether, M.P. 74-75 C. to yield the compound of this example.
EXADIPLE 2 5 -p/zenyl-2,2,3-trimeZhyl-2,3,4,5 -retrahydr0-1 H -2- benzazepinium chloride Suspend sodamide (from 3.72 g. of sodium) in 200 ml. of liquid ammonia and add 31.7 g. of o-dimethylaminomethyldiphenyl methane (Preparation 3). Stir the red solution for 30 minutes and then add 17.1 g. of propylene oxide. Stir and allow the ammonia to evaporate. Add ice water and extract the mixture with ether. Dry the ether solution and distil collecting that fraction boiling at 166167 C. (1.6 mm.) which consists of a-(2hydroxypropyl)-o-dimethylaminornethyl-diphenyl methane. Upon recrystallization from petroleum ether this substance melts at 91.592.5 C.
Dissolve 11.5 g. of the hydroxypropyl intermediate prepared above in 100 ml. of anhydrous benzene. Cool and slowly add 6 g. of thionyl chloride. Reflux for 30 minutes and concentrate to dryness in vacuo. Crystallize the residue from ethanol-ether to obtain ot-(2-chl0ropropyl)-odimethylarninomethyldiphenyl methane hydrochloride, M.P.155-156 C.
Treat the hydrochloride with aqueous sodium hydroxide and extract with ether. Dry the ether solution and concentrate to a residue. Heat the residue at 180190 C. for 10 minutes and crystallize from ethanol-ether obtaining the quaternary chloride of this example, M.P. 246- 249 C.
EXAMPLE 3 a- (ti-Ethoxyet/zyl) -0-dibenzylaminomethyldiphenyl methane The compound of this example is prepared via the first step in the alternate procedure of Example 1 utilizing postassium amide (from 2 g. of potassium), 250 ml. of liquid ammonia, 18.8 g. of o-dibenzylaminornethyldiphenyl methane and 7.7 g. of B-bromoethyl ether.
EXAMPLE 4 5-phenyl-2,2diberzzy[-2,3,4,5-tetrahydr0-1H-2- benzazepinium bromide Dissolve 12.5 g. of the compound of Example 3 in 100 ml. of 48% hydrobromic acid and reflux for 20-24 hours. Concentrate to a residue in vacuo and crystallize from ethanol-ether to obtain the quaternary salt of this example.
EXAMPLE 5 S-phanyl-Z-benzyl-2,3,4,5-tclrahydro-IH-Z-benzazepine Pyrolize the quaternary salt of Example 4 at 300320 C. collecting that distillate boiling at l-225 C./2.5 mm. The distillate cools to a glassy solid consisting of the compound of this example.
EXAMPLE 6 5-phenyl-2,3,4,5-tetrahydro-lH-Z-benzazepine Hydrogenate 3.5 g. of the compound of Example 5 in ml. of methanol in which is suspended 3.5 g. of
To a stirred mixture of 4.5 g. of the compound of Example 6, 100 ml. of anhydrous benzene and 2.0 g. of anhydrous sodium bicarbonate, add 4.0 g. of 2-phenethylbromide. Reflux and stir for 16-24 hours and add water. Separate the benzene layer, dry and concentrate in vacuo. The residue is an oil which slowly crystallizes yielding the compound of this example.
EXAMPLE 8 -phenyl-2,3-dimethyl-2,3,4,5-tetrahydr0-1H-2- benzazepine Pyrolize the quaternary salt of Example 2 at 300320 C. collecting that distillate boiling at 190-206 C./4.7 mm. Upon cooling, the distillate forms a glassy solid consisting of the compounds of this example. A maleate salt prepared from the base and maleic acid in a known manner melts at 119-121 C.
I claim:
1. A member of the group consisting of a benzazep-ine having the formula:
and the non-toxic acid addition salts and quaternary salts thereof wherein X is a member of the group consisting of H and methyl and R is a member of the group consisting of H, lower alkyl and phenyl lower alkyl.
2. Z-methyl-S-phenyl-Z,3,4,5 tetrahydro IH-Z-benzazepine.
3. A non-toxic acid addition salt of 2-methyl-S-phenyl- 2,3,4,5-tetrahwdro=1H-2-benzazepine.
4. 5-p'henyl-2,2,3-trimethyl-2,3,4,5 tetrahydro-lH-Z- benzazepinium chloride.
5. 5-phenyl-2,2-dibenzyl-2,3,4,5 tetrahydro-1H2-benzazepinium bromide.
6. 5-phenyl-2-benzyl-2,3,4,5 tetrahydro-1H-2-benzazepine.
7. 5-phenyl-2,3,4,5-tetra hydro-1H-2-benzazepine.
8. 5-phenyl-2-phenethyl-2,3,4,5 tetrahydro-lH-Z-benzazepine.
9. 5-phenyl-2,2dimethyl-2,3,4,5-tetrahydro-1H-2 oenZ- azepinium bromide.
10. 5-phenyl-2,3 dimethyl-2,3,4,5 tetrahydro-lH-Z- benzazepine.
11. In the process for preparing a 5-phenyl-2,3,4,5- tetrahydro-1H-2-benzazepine, the acid addition salts and quaternary ammonium salt thereof, the step which comprises heating at an elevated temperature a member of the group consisting of an o-R R -aminoethyldiphenylmethane and the acid addition salts thereof, having a lower alkyl group of at least two carbon atoms attached to the methane carbon atoms, the B-carbon atom of said alkyl group bearing a substituent selected from the group consisting of R R -amino and halogeno, wherein R and R are members of the group consisting of methyl and benzyl until substantial transformation into a tetrahydrobenzazepine compound is effected.
References Cited by the Examiner UNITED STATES PATENTS 2,520,264 8/1950 Walter 260239 2,684,962 7/1954 Walter 260239 2,956,072 10/1960 Bloom 260456 2,962,514 11/1960 Carbon et al. 260-456 NICHOLAS S. RIZZO, Primary Examiner.

Claims (2)

1. A MEMBER OF THE GROUP CONSISTING OF A BENZAZEPINE HAVING THE FORMULA:
11. IN THE PROCESS FOR PREPARING A 5-PHENYL-2,3,4,5TETRAHYDRO-1H-2-BENZAZEPINE, THE ACID ADDITION SALTS AND QUATERNARY AMMONIUM SALT THEREOF, THE STEP WHICH COMPRISES HEATING AT AN ELEVATED TEMPERATURE A MEMBER OF THE GROUP CONSISTING OF AN O-R1R2-AMINOETHYLDIPHENYLMETHANE AND THE ACID ADDITION SALTS THEREOF, HAVING A LOWER ALKYL GROUP OF AT LEAST TWO CARBON ATOMS ATTACHED TO THE METHANE CARBON ATOMS, THE B-CARBON ATOM OF SAID ALKYL GROUP BEARING A SUBSTITUENT SELECTED FROM THE GROUP CONSISTING OF R1R2-AMINO AND HALOGENO, WHEREIN R1 AND R2 ARE MEMBERS OF THE GROUP CONSISTING OF METHYL AND BENZYL UNTIL SUBSTANTIAL TRNASFORMATION INTO A TETRAHYDRO-BENZAZEPINE COMPOUND IS EFFECTED.
US296431A 1963-07-22 1963-07-22 Phenyl-benzazepines and methods for their manufacture Expired - Lifetime US3225031A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US296431A US3225031A (en) 1963-07-22 1963-07-22 Phenyl-benzazepines and methods for their manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US296431A US3225031A (en) 1963-07-22 1963-07-22 Phenyl-benzazepines and methods for their manufacture

Publications (1)

Publication Number Publication Date
US3225031A true US3225031A (en) 1965-12-21

Family

ID=23141969

Family Applications (1)

Application Number Title Priority Date Filing Date
US296431A Expired - Lifetime US3225031A (en) 1963-07-22 1963-07-22 Phenyl-benzazepines and methods for their manufacture

Country Status (1)

Country Link
US (1) US3225031A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2054638A1 (en) * 1969-07-17 1971-04-23 Allen & Hanburys Ltd
US3985731A (en) * 1974-07-01 1976-10-12 E. R. Squibb & Sons, Inc. 2H-2-benzazepin-1,3-diones
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20070054129A1 (en) * 2005-09-07 2007-03-08 Kalkanoglu Husnu M Solar Heat Reflective Roofing Membrane and Process For Making the Same
US20080026183A1 (en) * 2005-04-07 2008-01-31 Sophie Vanpoulle Biocidal roofing granules, roofing products including such granules, and process for preparing same
US20080261007A1 (en) * 2007-04-19 2008-10-23 Hong Keith C Post-functionalized roofing granules, and process for preparing same
WO2010012812A1 (en) * 2008-07-31 2010-02-04 Westfälische Wilhelms Universität Münster Benzazepines and benzazocines as sigma-receptor ligandes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2520264A (en) * 1947-08-26 1950-08-29 Maltbie Lab Inc Substituted 3, 1-benz-2, 3, 4, 5-tetrahydroazepines
US2684962A (en) * 1953-03-05 1954-07-27 Maltbie Lab Inc 3-beta hydroxyalkyl-3, (1) benz-2-3-4-5 tetrahydro-azepines
US2956072A (en) * 1957-07-08 1960-10-11 Pfizer & Co C N-(1-naphthyl)-n'-(beta-substituted ethyl)-ureas
US2962514A (en) * 1958-07-07 1960-11-29 Abbott Lab p-substituted benzenesulfonyl cyclopropane intermediate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2520264A (en) * 1947-08-26 1950-08-29 Maltbie Lab Inc Substituted 3, 1-benz-2, 3, 4, 5-tetrahydroazepines
US2684962A (en) * 1953-03-05 1954-07-27 Maltbie Lab Inc 3-beta hydroxyalkyl-3, (1) benz-2-3-4-5 tetrahydro-azepines
US2956072A (en) * 1957-07-08 1960-10-11 Pfizer & Co C N-(1-naphthyl)-n'-(beta-substituted ethyl)-ureas
US2962514A (en) * 1958-07-07 1960-11-29 Abbott Lab p-substituted benzenesulfonyl cyclopropane intermediate

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2054638A1 (en) * 1969-07-17 1971-04-23 Allen & Hanburys Ltd
US3985731A (en) * 1974-07-01 1976-10-12 E. R. Squibb & Sons, Inc. 2H-2-benzazepin-1,3-diones
US20080026183A1 (en) * 2005-04-07 2008-01-31 Sophie Vanpoulle Biocidal roofing granules, roofing products including such granules, and process for preparing same
US9980480B2 (en) 2005-04-07 2018-05-29 Certainteed Corporation Biocidal roofing granules, roofing products including such granules, and process for preparing same
US8791101B2 (en) 2005-07-15 2014-07-29 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20150023900A (en) * 2005-07-15 2015-03-05 알바니 몰레큘라 리써치, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20080207595A9 (en) * 2005-07-15 2008-08-28 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2009508807A (en) * 2005-07-15 2009-03-05 エーエムアール テクノロジー インコーポレイテッド Aryl and heteroaryl substituted tetrahydrobenzazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
US9403776B2 (en) 2005-07-15 2016-08-02 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR101594898B1 (en) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1904069A4 (en) * 2005-07-15 2010-08-18 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20110046114A1 (en) * 2005-07-15 2011-02-24 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2013006867A (en) * 2005-07-15 2013-01-10 Albany Molecular Research Inc Aryl- and heteroaryl-substituted tetrahydrobenzazepine and use of the same to block reuptake of norepinephrine, dopamine and serotonin
US20070021408A1 (en) * 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9044921B2 (en) 2005-09-07 2015-06-02 Certainteed Corporation Solar heat reflective roofing membrane and process for making the same
US20070054129A1 (en) * 2005-09-07 2007-03-08 Kalkanoglu Husnu M Solar Heat Reflective Roofing Membrane and Process For Making the Same
US10245816B2 (en) 2005-09-07 2019-04-02 Certainteed Corporation Solar heat reflective roofing membrane and process for making the same
US20080261007A1 (en) * 2007-04-19 2008-10-23 Hong Keith C Post-functionalized roofing granules, and process for preparing same
DE102008035596A1 (en) * 2008-07-31 2010-02-04 Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts Derivatives of benzoannated nitrogen heterocycles
WO2010012812A1 (en) * 2008-07-31 2010-02-04 Westfälische Wilhelms Universität Münster Benzazepines and benzazocines as sigma-receptor ligandes

Similar Documents

Publication Publication Date Title
EP0179383B1 (en) 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
EP0170213B1 (en) Glutarimide antianxiety and antihypertensive agents
KR840002427B1 (en) Process for preparing morpholine derivatives
GB1567862A (en) Tetracyclic derivatives
DK141624B (en) Analogous process for preparing morphinan derivatives.
US3074931A (en) Dibenzazepines
GB1581500A (en) Pyridobenzodiazepines
US3225031A (en) Phenyl-benzazepines and methods for their manufacture
CA1204745A (en) Hexahydronaphth (1,2-b) -1,4 -oxazines
NZ195423A (en) 6-phenyl-1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
GB2120662A (en) New azepinoindoles, their production and pharmaceutical compositions containing them
US3859304A (en) 6-halo-1-aminomethyl-1,2,3,4-tetrahydrocarbazoles
US4612312A (en) Glutarimide antianxiety and antihypertensive agents
IL29467A (en) N-phenyl indoline derivatives
US3242164A (en) Certain benzazepine compounds and their preparation
AU2006228426A1 (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
DE3780649T2 (en) CONDENSED BENZAZEPINE.
US4772705A (en) Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines
KR910002564B1 (en) Method for preparing hexahydropyrrolo [2,1-a] isoquinoline derivatives
US4247697A (en) 3-Phenoxy morphinans and their derivatives
EP0033632B1 (en) 7,8-amino, hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines, process for their preparation and pharmaceutical compositions containing them
US4409218A (en) Analgesic method
AU622506B2 (en) Novel derivatives of 1,7-(imidazo-(1,2-a)pyridine)5'-6'h) ones
US3526631A (en) Oximes of dibenzo(a,d)cyclohepten-5-ones
EP0743946A1 (en) 5ht2b receptor antagonists condensed indoles